used a PSA cutoff level ≤ 0.2 ng/ml in an open-label, phase 2 trial that assessed the effectiveness of Enzalutamide and external beam RT for intermediate risk prostate cancer (17, 32). The gene discussed is KLK3; the disease is prostate cancer.